⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYTX News
Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
globenewswire.com
KYTX
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
globenewswire.com
KYTX